TIMING of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation
NCT ID: NCT02961348
Last Updated: 2024-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
888 participants
INTERVENTIONAL
2017-02-15
2024-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
New Oral Anticoagulants (NOAC) in Stroke Patients
NCT03826927
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation
NCT03021928
Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2
NCT07139314
Early Versus Late Initiation of Anticoagulation in Mild-to-moderate AIS Patients With NVAF
NCT06057467
Novel Oral Anticoagulants in Stroke Patients
NCT02353585
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The intervention in this study will be timing of treatment onset. The choice of NOAC (i.e. apixaban, dabigatran, edoxaban or rivaroxaban) after the acute ischemic stroke is at the discretion of the treating physician.
This study will use the Swedish Stroke Register for enrolment, randomization and follow-up, with additional data linkage from other mandatory national registers. Primary outcome will be assessed at 90 days and secondary outcomes (including all-cause mortality and health economic analyses) and will be assessed at 90 days and up to one year after the index ischemic stroke.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Early start of NOAC
Day 1 to day 4 after ischemic stroke onset
Early start of NOAC
Initiation of NOAC up until day 4 after acute ischemic stroke in patients with atrial fibrillation
Late start of NOAC
Day 5 to day 10 after ischemic stroke onset
Late start of NOAC
Initiation of NOAC between day 5 and day 10 after acute ischemic stroke in patients with atrial fibrillation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Early start of NOAC
Initiation of NOAC up until day 4 after acute ischemic stroke in patients with atrial fibrillation
Late start of NOAC
Initiation of NOAC between day 5 and day 10 after acute ischemic stroke in patients with atrial fibrillation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eligible and willing to start (or re-start) NOAC
* Registered in The Swedish Stroke Register
* Signed informed consent
Exclusion Criteria
* Ongoing therapy with NOAC (without ≥2 days interruption at index stroke)
* International normalized ratio (INR)\>1.7
* No second brain imaging (CT/MRI) after thrombolysis/thrombectomy
* Previous randomization in the TIMING study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Swedish Stroke Register (Riksstroke)
UNKNOWN
Uppsala University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jonas Oldgren, MD. PhD
Role: PRINCIPAL_INVESTIGATOR
Dept of Medical Sciences, Uppsala University, Sweden
Signild Åsberg, MD. PhD
Role: PRINCIPAL_INVESTIGATOR
Dept of Medical Sciences, Uppsala University, Sweden
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alingås Hospital
Alingsås, , Sweden
Enköping Hospital
Enköping, , Sweden
Mälarsjukhuset Hospital
Eskilstuna, , Sweden
Falu Hospital
Falun, , Sweden
Gävle Hospital
Gävle, , Sweden
Sahlgrenska University Hospital Östra
Gothenburg, , Sweden
Sahlgrenska University Hospital
Gothenburg, , Sweden
Hallands Hospital
Halmstad, , Sweden
Hässleholm Hospital
Hässleholm, , Sweden
Helsingborg Hospital
Helsingborg, , Sweden
Karolinska University Hospital - Huddinge
Huddinge, , Sweden
Hudiksvalls sjukhus
Hudiksvall, , Sweden
Ryhov
Jönköping, , Sweden
Kalmar Hopsital
Kalmar, , Sweden
Länssjukhuset Kalmar
Kalmar, , Sweden
Kiruna Hospital
Kiruna, , Sweden
Köping Hospital
Köping, , Sweden
Kungälv Hospital
Kungälv, , Sweden
Lindesberg Hospital
Lindesberg, , Sweden
Lund
Lund, , Sweden
Malmö University Hospital
Malmo, , Sweden
Motala Hospital
Motala, , Sweden
Sahlgrenska Universitetssjukhuset Mölndal
Mölndal, , Sweden
Nyköping Hospital
Nyköping, , Sweden
Oskarshamn Hospital
Oskarshamn, , Sweden
Örebro University Hospital
Örebro, , Sweden
Skaraborg Hospital
Skövde, , Sweden
Karolinska University Hospital
Solna, , Sweden
Capio S:t Görans Hospital
Stockholm, , Sweden
Danderyd University Hospital
Stockholm, , Sweden
Södersjukhuset
Stockholm, , Sweden
Sundsvall County Hospital
Sundsvall, , Sweden
University Hospital of Umeå
Umeå, , Sweden
Uppsala University Hospital
Uppsala, , Sweden
Hallands Hospital
Varberg, , Sweden
Västerås Hospital
Västerås, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Asberg S, Hijazi Z, Norrving B, Terent A, Ohagen P, Oldgren J. Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial. Trials. 2017 Dec 2;18(1):581. doi: 10.1186/s13063-017-2313-9.
Oldgren J, Asberg S, Hijazi Z, Wester P, Bertilsson M, Norrving B; National TIMING Collaborators. Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study. Circulation. 2022 Oct 4;146(14):1056-1066. doi: 10.1161/CIRCULATIONAHA.122.060666. Epub 2022 Sep 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-00881
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
U-2015-341
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.